KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Accumulated Expenses: 2011-2012

Historic Other Accumulated Expenses for Halozyme Therapeutics (HALO) over the last 2 years, with Dec 2012 value amounting to $1.5 million.

  • Halozyme Therapeutics' Other Accumulated Expenses rose 212.99% to $1.5 million in Q4 2012 from the same period last year, while for Dec 2012 it was $1.5 million, marking a year-over-year increase of 212.99%. This contributed to the annual value of $1.5 million for FY2012, which is 212.99% up from last year.
  • According to the latest figures from FY2012, Halozyme Therapeutics' Other Accumulated Expenses is $1.5 million, which was up 212.99% from $481,365 recorded in FY2011.
  • In the past 5 years, Halozyme Therapeutics' Other Accumulated Expenses registered a high of $1.5 million during FY2012, and its lowest value of $481,365 during FY2011.
  • Its 2-year average for Other Accumulated Expenses is $993,990, with a median of $993,990 in 2011.
  • Data for Halozyme Therapeutics' Other Accumulated Expenses shows a peak YoY skyrocketed of 212.99% (in 2012) over the last 5 years.
  • Yearly analysis of 2 years shows Halozyme Therapeutics' Other Accumulated Expenses stood at $481,365 in 2011, then skyrocketed by 212.99% to $1.5 million in 2012.